Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Lung cancer Treatment's hidden heart risk under the microscope

NCT ID NCT04305613

First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 26 times

Summary

This study follows 221 people with stage II or III lung cancer to see how chemoradiation therapy affects their hearts. Participants get heart scans and blood tests before, during, and for two years after treatment. The goal is to better understand and track heart damage caused by cancer therapy.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARDIOTOXICITY are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Abramson Cancer Center of the University of Pennsylvania

    Philadelphia, Pennsylvania, 19104, United States

  • Chester County Hospital

    West Chester, Pennsylvania, 19380, United States

  • Lancaster General Hospital

    Lancaster, Pennsylvania, 17601, United States

  • Montefiore Medical Center

    The Bronx, New York, 190467, United States

  • Rutger's University / Cancer Institute of New Jersey

    New Brunswick, New Jersey, 08901, United States

  • The Brigham and Women's Hospital

    Boston, Massachusetts, 02115, United States

  • University of Alabama

    Birmingham, Alabama, 35233, United States

  • Washington University School of Medicine

    St Louis, Missouri, 63110, United States

Conditions

Explore the condition pages connected to this study.